What is the current stock price of Catalyst Pharmaceuticals, Inc. (CPRX)?

As of the latest market data, Catalyst Pharmaceuticals, Inc. (CPRX) is trading at $31.32. The stock has seen a loss of -0.03% today.

Does Catalyst Pharmaceuticals, Inc. (CPRX) pay a dividend?

Based on current data, Catalyst Pharmaceuticals, Inc. does not have a confirmed active dividend policy.

What is the market cap of Catalyst Pharmaceuticals, Inc.?

The current market capitalization of Catalyst Pharmaceuticals, Inc. (CPRX) is approximately unavailable.

CPRX

Catalyst Pharmaceuticals, Inc.·Healthcare

31.32

0.032%(−0.01)

Close Price

31.50

0.575%(+0.18)

Pre-Market

Last Updated: — ET

52W L: $19.0552W H: $32.56

CPRX NEWS

zacks.com

20h ago

Why Catalyst Pharmaceutical (CPRX) is a Top Momentum Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

zacks.com

2d ago

Why Catalyst Pharmaceutical (CPRX) is a Top Value Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

zacks.com

May 14

CPRX or UTHR: Which Is the Better Value Stock Right Now?

Investors interested in stocks from the Medical - Drugs sector have probably already heard of Catalyst Pharmaceutical (CPRX) and United Therapeutics (UTHR). But which of these two stocks presents investors with the better value opportunity right now?

zacks.com

May 12

Catalyst Pharmaceuticals Q1 Earnings Beat, Firdapse Revenues Rise Y/Y

CPRX beats Q1 estimates driven by rising Firdapse and Agamree sales amid Angelini Pharma's pending $4.1B acquisition deal.

prnewswire.com

May 12

Are CPRX, UNF, RMAX, ACR Obtaining Fair Deals for their Shareholders?

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws

zacks.com

May 11

Catalyst (CPRX) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

The headline numbers for Catalyst (CPRX) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Company Profile

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company also develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3, as well as to treat hereditary neuropathy with liability to pressure palsies. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.

Sector

Healthcare

Industry

Biotechnology

Employees

181

IPO Date

2006-11-08

Beta

0.72

Websitewww.catalystpharma.com↗